Table 2

 Incidence of ANKENT in non-castrated and castrated B10.BR males, castrated B10.BR males with testosterone substitution, and in control and testosterone treated B10.BR females

No of miceTreatmentNo of ANKENT positive/total miceOccurrence of ANKENT (months)*% with ANKENT*
*Significant difference in the incidence of ANKENT was found between the control males and castrated males (p<0.01), and between castrated males and castrated males injected with Te (p<0.01).
Te, testosterone.
104 MalesNone9/1044, 5.5, 5.5, 6.5, 7, 8, 9, 9, 128.7
93 MalesCastration0/930
37 MalesCastration + Te3/376.5, 10, 118.1
30 FemalesNone0/300
32 FemalesTe0/320